Exagen Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Exagen Inc in the second quarter 2026?
Exagen Inc achieved a return on average equity (ROE) of 3.25 % in its second quarter 2026, this is above XGN's average return on equity of 0%.
Exagen Inc shareholder's equity over the 12 months ending in its second quarter 2026 are valued at $16 million

ROE decreased relative to the period ending , due to the decline in net income.

Within the Medical Laboratories industry Exagen Inc achieved the highest return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 650 to 651.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Equity Change	-41.92 %	125.39 %	82.9 %	40.95 %	-
Y / Y Net Income Change	-	-	-67.03 %	-	-
Net Income (TTM) in Millions	1	4	0	8	3
Return On Equity (TTM)	3.25 %	20.63 %	-0.32 %	54.81 %	20.26 %
XGN's Total Ranking	# 651	# 650	# 1816	# 54	# 476
Equity (TTM) in Millions	12	14	17	18	21
Seq. Equity Change	-15.35 %	-17.29 %	-3.8 %	-13.77 %	228.5 %
Seq. Net Income Change	-	-	-	-	-

Back to XGN Management Effectiveness >> XGN's 5 Years Annual ROE >> Compare XGN ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	#
Sector	#
Overall	# 651

Return On Equity Statistics
High	Average	Low
0 %	0 %	0 %

XGN Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	17	10	23	42	85
Y / Y Equity Change	82.9 %	-57.96 %	-46.55 %	-50.01 %	103.01 %
Net Income in Millions	0	0	0	0	0
Y / Y Net Income Change	-	-	-	-	-
Return On Equity	-0.29 %	-0.13 %	-0.15 %	0.66 %	-0.21 %

Back to XGN Management Effectiveness >> XGN's 5 Years Annual ROE >> Compare XGN ROE to its Competitors

More Return On Equity Ratios
Medical Laboratories Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
XGN's' Return on Equity at Yahoo Finance
XGN's Roe Ratio versus Medical Laboratories Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for XGN's Competitors
Subscribers only: Roe for Exagen Inc 's Suppliers
Subscribers only: Return On Equity for XGN's Customers

Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector	ROE
Utah Medical Products Inc	8.74 %
Vaso Corporation	8.65 %
Veracyte Inc	8.64 %
Corcept Therapeutics Inc	8.27 %
Integer Holdings Corporation	7.43 %
Pacific Health Care Organization Inc	7.42 %
Vericel Corporation	6.91 %
The Cooper Companies Inc	6.90 %
Siga Technologies Inc	6.74 %
Merck and Co Inc	6.59 %
Zimmer Biomet Holdings Inc	6.36 %
National Vision Holdings Inc	5.71 %
Conmed Corporation	5.51 %
Pfizer Inc	4.91 %
Privia Health Group Inc	4.23 %
Becton Dickinson And Company	3.79 %
Alkermes Plc	3.72 %
Lifemd Inc	3.47 %
Lifestance Health Group Inc	3.39 %
Revvity Inc	3.27 %
Bio rad Laboratories Inc	3.15 %
Envista Holdings Corporation	3.08 %
Immucell Corporation	2.68 %
Surgery Partners Inc	2.63 %
Mimedx Group Inc	2.61 %
Cormedix Inc	2.18 %
Atricure Inc	2.14 %
Pacira Biosciences inc	2.13 %
Warby Parker Inc	2.06 %
Repligen Corp	1.98 %

Date modified: 2026-09-26T07:36:46+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.